PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA

FIELD: chemistry.SUBSTANCE: in the general formula IRare selected from methyl, ethyl, propyl, cyclopropyl, cyclopropylmethyl, difluoroethyl and 2,2,2-trifluoroethyl; Ris selected from hydrogen, Calkyl, Calkyloxy, CalkylaminoCalkyl, Ccycloalkyl, saturated 4-6-membered heterocycloalkyl containing 1-2...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ACHAB Abdelgkhani Abe, DENG Jongki, KATTAR Solomon, MU Chanvej, E Bajtszyun, CHZHOU Khua, YAN Lipin, KATTS Dzhejson D, VAN Syaona, LEN Syanshen, ENTONI Nevill Dzhon, CHZHAN Zhun, MAKGOVAN Meredet, SHI Fen, ALTMAN Majkl D, FRADERA LINAS Fransesk Ksaver, FONG Kin Chiu, METOT Dzhon L, CHZHAN Sisin, KRISTOFER Mettyu P, CHZHAO Syaoli, GARSIYA Yudit
Format: Patent
Sprache:eng ; rus
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:FIELD: chemistry.SUBSTANCE: in the general formula IRare selected from methyl, ethyl, propyl, cyclopropyl, cyclopropylmethyl, difluoroethyl and 2,2,2-trifluoroethyl; Ris selected from hydrogen, Calkyl, Calkyloxy, CalkylaminoCalkyl, Ccycloalkyl, saturated 4-6-membered heterocycloalkyl containing 1-2 heteroatoms selected from nitrogen, oxygen or nitrogen and oxygen, phenyl and mono- or bicyclic Cheteroaryl containing in the ring 1 to 2 nitrogen atoms or a nitrogen atom and a sulphur atom, where Ris substituted with 0, 1, 2 or 3 Rsubstitutes; n is 1, 2, 3; A is selected from pyrrolidinyl, piperidinyl, azetidinyl, azaspiro[2.4]hept-7-yl and azepanyl; L is selected from NH and N(Calkyl); K is selected from a chemical bond, C(O), CH, -C(O)N(R)-(CH)- and Calkynylene; Ris H or Calkyl, m is 0, 1, 2, or 3; Rare independently selected from: halogen, Calkyl, Calkenyl, Calkyl(oxy), Calkyl(oxy)(carbonyl), Calkyl(carbonyl), phenyl(oxy), phenyl(oxy)(carbonyl), phenylCalkyl(oxy)(carbonyl), phenylCalkyl(carbonyl), Ccycloalkyl(carbonyl), CcycloalkylCalkyl, Cbicycloalkyl(carbonyl), Cspirocycloalkyl(carbonyl), 5-10 membered mono- or bicyclic heteroaryl containing 1 to 3 heteroatoms in a ring selected from nitrogen or nitrogen and sulphur, 5-10 membered mono- or bicyclic heteroaryl(carbonyl), wherein the heteroaryl contains 1 to 3 ring heteroatoms selected from nitrogen or nitrogen and / or sulphur, (C)heterocycloalkyl containing 1-2 heteroatoms selected from nitrogen and oxygen, (C)heterocycloalkyl (carbonyl), wherein heterocycloalkyl contains 1-2 heteroatoms selected from nitrogen and oxygen, Calkylamino(carbonyl), Ccycloalkylamino(carbonyl), -C(O)(Calkyl), -(Calkyl)COH, oxo(=O); CalkylS(O), amino, (Calkyl)amino, Cacylamino, hydroxyl, (Calkyl)OH, cyano; where Reach is substituted with 0, 1, 2 Rsubstitutes, and each Rare independently selected from halogen, Calkyl, Calkyl(oxy), phenyl, 5-6 membered heteroaryl containing an oxygen or nitrogen ring atom, (C) of heterocycloalkyl containing a nitrogen, oxygen or sulphur atom, or S(O)group in the ring, (C) heterocycloalkyl (carbonyl), wherein the heterocycloalkyl contains a nitrogen, oxygen or sulphur atom, or S(O)group in the ring, oxo(=O), amino, (Calkyl)amino, (Calkyl)OH, Calkoxy, cyano and Chaloalkyl. Invention also includes specific compounds as defined in claim 2.EFFECT: invention relates to a novel compound of formula I or a pharmaceutically acceptable salt or stereoisomer thereof, which have the properties of a PI3K-alpha i